aspartate aminotransferase, alanine aminotransferase, or y-glutamyltransferase were transient and asymptomatic.
Objective-To examine the effect of bronchodilator treatment given continuously versus on demand on the progression of asthma and chronic bronchitis and to compare the long term effects of a Pt2 adrenergic drug (salbutamol) and an antichoinergic drug (ipratropium bromide).
Design-Two year randomised controlled prospective crossover study in which patients were assigned to one of two paraliel treatment groups receiving continuous treatment or treatment on demand.
Setting-29 general practices in the catchment area of the University of Nijmegen.
Patients-223 patients aged :30 with moderate airway obstruction due to asthma or chronic bronchitis, selected by their general practitioners.
Interventions-1600 [tg salbutamol or 160 ig ipratropium bromide daily (113 patients) or salbutamol or ipratropium bromide only during exacerbations or periods of dyspnoea (110) . No other pulmonary treatment was permitted.
Main outcome measures-Decline in ventilatory finction and change in bronchial responsiveness, respiratory symptoms, number of exacerbations, and quality of life.
Results-Among 144 patients completing the study, after correction for possible confounding factors the decline in forced expiratory volume in one second was -0-072 1/year in continuously treated patients and -0-020 1/year in those treated on demand (p<O0O5), irrespective of the drug. The difference in the decline in patients with asthma was comparable with that in patients with chronic bronchitis (asthma: 0-092 v -0.025 1/year; chronic bronchitis: -0-082 v -0-031 1/year). Bronchial responsiveness increased slightly (0.4 doubling dose) with continuous treatment in chronic bronchitis, but exacerbations, symptoms, and quality of life were unchanged. Salbutamol and ipratropium bromide had comparable effects on all variables investigated. Conclusions-Continuous bronchodilator treatment without anti-inflammatory treatment accelerates decline in ventilatory function. Bronchodilators should be used only on demand, with additional corticosteroid treatment, if necessary.
Introduction
Asthma and chronic bronchitis are considered to be progressive diseases.' 2 The hypothesis has been put forward that early continuous bronchodilator treatment of reversible airflow obstruction will improve their prognosis, 3 Patients were randomly allocated to use salbutamol during one year and ipratropium bromide during the other in a crossover design (Fig 1) . The long term effects were expected to be less distinct with respect to the drug than to the treatment regimen, and the variation within patients was expected to be less than between patients. Therefore it was decided to use a crossover design for the drugs and not for the treatment regimen. All four treatment groups were equally represented in each general practice to exclude possible effects arising between doctors ("balanced allocation of treatment"). The study was of single blind design (blind observer) as most patients could easily distinguish between the (side) effects of the study drugs.
Patients who used the bronchodilator treatment on demand were instructed carefully that it should not be used to prevent symptoms but only to treat symptoms when present. The patients made an accurate weekly report of all treatment used. Patient 4-=severe complaints). A total score for each week was obtained by adding the three separate scores. Experienced health ("quality of life") was assessed with the Nottingham health profile'7 at the start of the study and after 12 and 24 months. The number and duration of exacerbations were assessed by the general practitioner. Exacerbations were defined according to Fletcher, modified according to Boman et al. 14 Smoking, allergy and treatment before study-History of smoking was retrospectively assessed in pack years, and during the study the number of cigarettes smoked each day was recorded weekly. Allergy was tested by means of seven radioallergosorbent tests (to pollen from weeds, grasses, and trees; cats and dogs; house dust mites; and Aspergillus fumigatus). Patients were considered to be allergic if at least one test result was positive. Information about pulmonary treatment used in the year preceding the study was provided by the general practitioner. Statistical analysis-To determine the sample size of the study population we estimated that a clinically relevant difference in decline in FEV1 between the two parallel treatment groups would be 0 04 l/year or more.
With a Pi value (1-,3=power) of 0 20 and an a value (significance level) of 0-05, the total number of patients completing the study had to be 156.
The principle of intention to treat was not used in the analysis as this study was more directed at fundamental questions concerning the therapeutic regimen than at its feasibility. (12) 12 (17) 19 (3) 13 (5) 9 (2) Effects on decline in FEV1-Decline in FEV1 in 14 (20) 13 (2) 60 (24)*** 22 (5) continuously treated patients was -0-086 1/year and in study group with crossover treatment and three other patients treated on demand -0-029 1/year. 0-111 1/year) (p<0-05) (fig 2) . After correction for possible confounding factors (such as sex, age, height, smoking habits, and initial FEVy) the decline was -0-072 1/year for continuously treated patients and -0-020 1/year for those treated on demand. The difference was 0-052 1/year (0 to 0-1061/year) (p=0-05). The difference in decline between the two treatments in patients with chronic bronchitis (-0-082 (continuous) v -0-031 (on demand) 1/year) was comparable with the decline in patients with asthma (-0-092 v -0-025 1/year). Patients who smoked during the study showed a decline in lung function comparable with that in non-smokers, both those treated continuously and those treated on demand (fig 2) . An additional analysis in which the patients who dropped out of the study were included as long as they participated confirmed these results: the regression slope for continuously treated patients was 0-097 (SE (12) 53 (12) 50 (12) 53 (14) 52 (13) 
Mean(SD)FEVINVC(%)
59 (18) 65(13)* 64 (13) 58 (15) 64 (16) 64 (15) Mean (SD) reversibility of obstruction(%) 24 (23) 11 (12)** 12 (12) 19 (21) 17 (19) 14 (20) Geometric mean PC20 (g histamine/1)
*p<0.05, **p<0-001, differences between asthma and chronic bronchitis and between all four treatment groups.
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7 p<005, one sample proportion test; 27/83 patients had no preference); patients who had used the drugs continuously did not show this preference (20/60, 33% v 21/60, 35%; 19/60 had no preference).
Discussion
The results of this study do not confirm the hypothesis that continuous bronchodilator treatment reduces the decline in ventilatory function in patients with moderate airflow obstruction. Continuously treated patients had an annual decline in FEV1 that was three to four times higher than that in patients treated on demand. The annual decline in the group treated on demand was comparable with that in asthmatic and bronchitic subjects in a sample from the general population.'9 The difference in decline was not caused by different conditions of the treatment groups at the start of the study, as the decline was corrected for possible confounding variables-for example, sex, past and current smoking behaviour, and initial FEV1. No influence of these variables was evident (all p values >0 8) . Previous treatment was not a confounder either: coninuously treated patients had not received more corticosteroids or cromoglycate in the year preceding the study than patients treated on demand.
The short period of this study could discriminate decline in FEV1 between the two treatment regimens because of three reasons: firstly, a relatively large number of patients was studied; secondly, seven measurements of FEV1 were used; and, thirdly, the data for FEV1 fitted clearly in a linear model (explained variations of the measurements were more than 90%).
Continuous bronchodilation seems to worsen rather than improve the prognosis, as far as the decline in FEV1 is concerned. This might be explained by bronchodilators failing to influence the inflammatory processes underlying the disease. A long term continuous bronchodilator treatment without antiinflammatory treatment could lead to adverse effects.7820 In this study continuous bronchodilator treatment tended to increase bronchial responsiveness when compared with treatment on demand but only significantly so in patients with chronic bronchitis during part of the study. The need for antiinflammatory treatment was emphasised by the observation that the condition of most of the 40 patients who dropped out of the study because of insufficient bronchodilator treatment improved after the use of corticosteroids. Two thirds of these patients were treated continuously with bronchodilators during the study.
Although FEV1 clearly declined in continuously treated patients, the decline was not accompanied by a significant increase in exacerbations and symptoms or a perceived poorer quality of life. Patients with continuous bronchodilator treatment may tolerate precipitating situations better and may therefore be more exposed to sensitising agents.8 Continuous bronchodilation without anti-inflammatory treatment probably masks the decline in ventilatory function and suppresses the subjective need for additional anti-inflammatory treatment."2 Lack of awareness of this decline may mislead both doctor and patient and may be a reason why many patients in general practice who actually need anti-inflammatory treatment are still treated with only bronchodilators, not only in the Netherlands'" but also in the United Kingdom22 and probably in many other countries. A combination of bronchodilators and inhaled corticosteroids is advised when the need for bronchodilators is increasing.27
Recently, comparable findings were presented by Sears et al.8 Regular inhalation of the 12 adrenergic drug fenoterol for six months was associated with poorer overall control in 40 of their 64 asthmatic subjects. Control of asthma was judged by peak flow rates, symptom diaries, and use of additional treatment. Although that study was the longest study so far, it was too short to examine the effect on decline in ventilatory function. As continuous use of both salbutamol and ipratropium bromide and, from the study of Sears et al,8 fenoterol seems to have adverse effects on the control of the disease it is likely that these effects are not specific to one certain drug but to bronchodilators generally. Moreover, as the results of our study were comparable for asthma and chronic bronchitis the possible deleterious effects of the continuous use of bronchodilators seems applicable to both conditions.
No '4 In addition, a review article on assessing the need for total hip replacements has recently been published. '5 But there is no routine statistical information available about readmissions or deaths after the operation. We used the Oxford record linkage study to report operation rates, postoperative mortality, and readmission rates in a large, defined population. As these data show that postoperative mortality varies considerably depending on whether the arthroplasty is elective or the result ofan emergency admission, this report is confined to elective hip arthroplasty; our findings on post-traumatic operations will be reported elsewhere.
Methods

RECORDS
The Oxford record linkage study is a collection of computerised abstracts of hospital records and death certificates collected such that data on successive events relating to the same patient can be linked together. Death records were available for all patients in the study area regardless of place of death. We analysed data on hospital admissions in 1976-85, when data collection was undertaken in six districts of the Oxford region, covering a resident population of 19 million. The record linkage study collects data on all patients admitted to hospital for NHS care. Hospitals that treat private patients have been invited to submit data, but their submission of data on private care has been inconsistent. Unless otherwise indicated the results in this study refer to NHS operations only.
All records that included the Office of Population Censuses and Surveys operation code for total hip replacement (810) were identified.'6 Unfortunately only a few hospitals used the optional code (810 5) to distinguish between primary and revision replacements. Patients with femoral fracture were excluded. A validation study of coding was undertaken in one hospital, which performed about half the hip replacements in the region, by cross checking between the record linkage study files and the hospital's operating theatre registers.
All hip replacements undertaken in the six districts were included in the calculations of incidence of the operation. In the analysis of postoperative mortality patients who had had a second operation in the 90 days after a first arthroplasty were excluded, so all the
